|
1
|
Kanthan R, Loewy J and Kanthan SC:
Skeletal metastases in colorectal carcinomas: A Saskatchewan
profile. Dis Colon Rectum. 42:1592–1597. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Besbeas S and Stearns MW Jr: Osseous
metastases from carcinomas of the colon and rectum. Dis Colon
Rectum. 21:266–268. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chang CY, Peng YJ, Shen DH, Huang WS and
Cherng SC: Detection of multiple myeloma by PET/CT in a patient
with colon cancer. Clin Nucl Med. 33:367–370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yermiahu T, Peiser J, Benharroch D and
Ovnat A: Aggressive behavior of carcinoma of the colon associated
with nonsecreting plasma cell myeloma. A case report. J Clin
Gastroenterol. 11:565–567. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zaidi AA and Vesole DH: Multiple myeloma:
An old disease with new hope for the future. CA Cancer J Clin.
51:273–285. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan D, Chng WJ, Chou T, Nawarawong W,
Hwang SY, Chim CS, Chen W, Durie BG and Lee JH: Management of
multiple myeloma in Asia: Resource-stratified guidelines. Lancet
Oncol. 14:e571–e581. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kyle RA: Multiple myeloma. An update on
diagnosis and management. Acta Oncol. 29:1–8. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kyle RA and Rajkumar SV: Criteria for
diagnosis, staging, risk stratification and response assessment of
multiple myeloma. Leukemia. 23:3–9. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kyle RA, Therneau TM, Rajkumar SV,
Remstein ED, Offord JR, Larson DR, Plevak MF and Melton LJ III:
Long-term follow-up of IgM monoclonal gammopathy of undetermined
significance. Blood. 102:3759–3764. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Snozek CLH, Katzmann JA, Kyle RA,
Dispenzieri A, Larson DR, Therneau TM, Melton LJ III, Kumar S,
Greipp PR, Clark RJ, et al: Prognostic value of the serum free
light chain ratio in newly diagnosed myeloma: Proposed
incorporation into the international staging system. Leukemia.
22:1933–1937. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
International Myeloma Working Group:
Criteria for the classification of monoclonal gammopathies,
multiple myeloma and related disorders: A report of the
International Myeloma Working Group. Br J Haematol. 121:749–757.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jadvar H and Conti PS: Diagnostic utility
of FDG PET in multiple myeloma. Skeletal Radiol. 31:690–694. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schirrmeister H, Bommer M, Buck AK, Müller
S, Messer P, Bunjes D, Döhner H, Bergmann L and Reske SN: Initial
results in the assessment of multiple myeloma using
18F-FDG PET. Eur J Nucl Med Mol Imaging. 29:361–366.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rajkumar SV: Treatment of myeloma: Cure
vs. control. Mayo Clin Proc. 83:1142–1145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haessler J, Shaughnessy JD Jr, Zhan F,
Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M,
Zangari M, Hollmig K, et al: Benefit of complete response in
multiple myeloma limited to high-risk subgroup identified by gene
expression profiling. Clin Cancer Res. 13:7073–7079. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kumar S, Giralt S, Stadtmauer EA,
Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S,
Munshi N, Niesvizky R, et al: International Myeloma Working Group:
Mobilization in myeloma revisited: IMWG consensus perspectives on
stem cell collection following initial therapy with thalidomide-,
lenalidomide-, or bortezomib-containing regimens. Blood.
114:1729–1735. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Palumbo A, Sezer O, Kyle R, Miguel JS,
Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld
P, et al: IMWG: International Myeloma Working Group guidelines for
the management of multiple myeloma patients ineligible for standard
high-dose chemotherapy with autologous stem cell transplantation.
Leukemia. 23:1716–1730. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Attal M, Harousseau JL, Stoppa AM, Sotto
JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah
N, et al: A prospective, randomized trial of autologous bone marrow
transplantation and chemotherapy in multiple myeloma. Intergroupe
Français du Myélome. N Engl J Med. 335:91–97. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Child JA, Morgan GJ, Davies FE, Owen RG,
Bell SE, Hawkins K, Brown J, Drayson MT and Selby PJ: Medical
Research Council Adult Leukaemia Working Party: High-dose
chemotherapy with hematopoietic stem-cell rescue for multiple
myeloma. N Engl J Med. 348:1875–1883. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blade J, Vesole DH and Gertz M:
Transplantation for multiple myeloma: Who, when, how often? Blood.
102:3469–3477. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kumar A, Loughran T, Alsina M, Durie BG
and Djulbegovic B: Management of multiple myeloma: A systematic
review and critical appraisal of published studies. Lancet Oncol.
4:293–304. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fermand JP, Ravaud P, Chevret S, Divine M,
Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X,
et al: High-dose therapy and autologous peripheral blood stem cell
transplantation in multiple myeloma: Up-front or rescue treatment?
Results of a multicenter sequential randomized clinical trial.
Blood. 92:3131–3136. 1998.PubMed/NCBI
|
|
23
|
Facon T, Mary JY, Harousseau JL, et al:
Front-line or rescue autologous bone marrow transplantation (ABMT)
following a first course of high dose melphalan (HDM) in multiple
myeloma (MM). Preliminary results of a prospective randomized trial
(CIAM) protocol. Blood. 88(Suppl 1): 685a1996.
|
|
24
|
Barlogie B, Kyle R, Anderson K, et al:
Comparable survival in multiple myeloma (MM) with high dose therapy
(HDT) employing MEL 140 mg/m2 TBI 12 Gy autotransplants
vs. standard dose therapy with VBMCP and no benefit from interferon
(IFN) maintenance: Results of intergroup Trial S9321. Blood.
102:42a2003.
|
